satavaptan has been researched along with clonidine in 1 studies
| Studies (satavaptan) | Trials (satavaptan) | Recent Studies (post-2010) (satavaptan) | Studies (clonidine) | Trials (clonidine) | Recent Studies (post-2010) (clonidine) |
|---|---|---|---|---|---|
| 95 | 11 | 30 | 13,692 | 2,044 | 1,394 |
| Protein | Taxonomy | satavaptan (IC50) | clonidine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.101 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0353 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0115 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 5.365 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.21 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 5.365 | |
| Alpha-2A adrenergic receptor | Bos taurus (cattle) | 0.002 | |
| Nischarin | Rattus norvegicus (Norway rat) | 0.3662 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbier, A; Elena, PP; Lacheretz, F; Le Fur, G; Maffrand, JP; Serradeil-Le Gal, C | 1 |
1 other study(ies) available for satavaptan and clonidine
| Article | Year |
|---|---|
Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension.
Topics: Administration, Oral; Administration, Topical; Animals; Antidiuretic Hormone Receptor Antagonists; Cell Membrane; Clonidine; Disease Models, Animal; Injections, Intravenous; Intraocular Pressure; Kidney; Male; Morpholines; Ocular Hypertension; Rabbits; Receptors, Vasopressin; Safety; Spiro Compounds; Timolol | 2000 |